Skip to main content
. 2017 Oct 17;35(36):4003–4011. doi: 10.1200/JCO.2017.75.8177

Fig 3.

Fig 3.

(A) Moderate-severe chronic graft-versus-host disease (cGVHD)–free survival. (B) Overall survival (OS). (C) cGVHD and relapse-free survival (cGRFS). (D) Progression-free survival (PFS). (E) Nonrelapse mortality (NRM). (F) Disease relapse. Log-rank test was used for group comparison for (A) to (D) and Gray test for (E) and (F). ATLG, anti–T-lymphocyte globulin.